254744-55-3Relevant academic research and scientific papers
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
-
, (2008/06/13)
Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutica
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
-
, (2008/06/13)
Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutica
Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists
Murugesan, Natesan,Tellew, John E.,Gu, Zhengxiang,Kunst, Bridgette L.,Fadnis, Leena,Cornelius, Lyndon A.,Baska, Rose Ann F.,Yang, Yifan,Beyer, Sophie M.,Monshizadegan, Hossain,Dickinson, Kenneth E.,Panchal, Balkrushna,Valentine, Maria T.,Chong, Saeho,Morrison, Richard A.,Carlson, Kenneth E.,Powell, James R.,Moreland, Suzanne,Barrish, Joel C.,Kowala, Mark C.,Macor, John E.
, p. 3829 - 3835 (2007/10/03)
The ETA receptor antagonist (2) (N-(3,4-dimethyl-5-isoxazolyl)-4′-(2-oxazolyl)-[1,1′-biphenyl] -2-sulfonamide, BMS-193884) shares the same biphenyl core as a large number of AT1 receptor antagonists, including irbesartan (3). Thus, i
